Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Breakthrough Monarch eTNS System® Discovered for Drug-Resistant Epilepsy (DRE)

NeuroSigma, discovered breakthrough Monarch eTNS System® Drug-Resistant Epilepsy (DRE).

Monarch eTNS System® is designed for individuals with 18 years of age or older to lower the frequency of seizures diagnosed with epilepsy specified by partial-onset seizures, with or without secondary generalization, that are refractory to two or more antiepileptic medications.

Monarch eTNS System helps in providing more effective treatments for life-threatening or irreversibly debilitating human diseases and conditions.

It is observed that 30 per cent of epilepsy patients consists of Drug-resistant epilepsy (DRE). Some of the serious complications observed in DRE are psychological disorders, rising death rates and other severely debilitating conditions.

Alternatives to antiepileptic drugs (AEDs) and surgery are a significant unmeed medical need for patients with incomplete seizure control.

Compared with adjunctive pharmaceutical and implantable device therapies, the results achieved with clinical trials of Monarch eTNS System® has shown positive results. Moreover, for various number of serious diseases, Monarch eTNS System is demonstrated to be the safe and effective alternative to drug-based or surgical treatments.

US Food and Drug Administration (FDA) grants Breakthrough Device Designation for Monarch eTNS System®.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024